Vyriad has a total of 25 patents globally, out of which none have been granted. Of these 25 patents, more than 88% patents are active. The United States of America seems to be the main focused R&D centre and also is the origin country of Vyriad.
Vyriad was founded in 2015. Vyriad is developing the next generation of targeted genetic therapeutics by engineering viruses, viral vectors, and viral envelope glycoproteins to deliver genes directly to specified cells. Oncolytic virotherapy, in vivo gene treatments, and gene editing applications are made easier by this targeted approach.
Do read about some of the most popular patents of Vyriad which have been covered by us in this article and also you can find Vyriad patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Vyriad patent portfolio.
How many patents does Vyriad have?
Vyriad has a total of 25 patents globally. These patents belong to 5 unique patent families. Out of 25 patents, 22 patents are active.
How Many Patents did Vyriad File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Vyriad Applications Filed | Vyriad Patents Granted |
| 2023 | 2 | – |
| 2022 | 1 | – |
| 2021 | 14 | – |
| 2020 | 7 | – |
| 2019 | 1 | – |
How many Vyriad patents are Alive/Dead?
Worldwide Patents
How Many Patents did Vyriad File in Different Countries?
Countries in which Vyriad Filed Patents
| Country | Patent |
| Canada | 3 |
| United States Of America | 3 |
| New Zealand | 2 |
| Mexico | 2 |
| Israel | 2 |
| Europe | 2 |
| Australia | 2 |
| Japan | 1 |
| Singapore | 1 |
| Hong Kong (S.A.R.) | 1 |
| South Africa | 1 |
| India | 1 |
Where are Research Centers of Vyriad Patents Located?
The Research Center of Vyriad is in the United States of America.
List of Vyriad patents
| Vyriad Patents | Title |
| US20230184765A1 | Detection Assays For Coronavirus Neutralizing Antibodies |
| US20230149536A1 | Compositions For Treating And/Or Preventing Coronavirus Infections |
| US20220178910A1 | Ifnbeta As A Pharmacodynamic Marker In Vsv-Ifnbeta-Nis Oncolytic Therapy |
| EP4136457A1 | Detection Assays For Coronavirus Neutralizing Antibodies |
| EP3946421A4 | Ifnbeta As A Pharmacodynamic Marker In Vsv-Ifnbeta-Nis Oncolytic Therapy |
| WO2023159102A1 | Combinations Of Checkpoint Inhibitors And Oncolytic Virus For Treating Cancer |
| CA3180508A1 | Detection Assays For Coronavirus Neutralizing Antibodies |
| CA3134957A1 | Ifn.Beta. As A Pharmacodynamic Marker In Vsv-Ifn.Beta.-Nis Oncolytic Therapy |
| CA3104509A1 | Methods Of Treating Cancer Using Combination Therapy |
| AU2021256894A1 | Detection Assays For Coronavirus Neutralizing Antibodies |
| AU2020244878A1 | Ifn-Β As A Pharmacodynamic Marker In Vsv-Ifn-Β-Nis Oncolytic Therapy |
| JP2023524200A | Detection Assay For Coronavirus Neutralizing Antibodies |
| IL297237A | Detection Assays For Coronavirus Neutralizing Antibodies |
| IL286724A | Ifnbeta As A Pharmacodynamic Marker In Vsv-Ifnbeta-Nis Oncolytic Therapy |
| SG11202110697UA | Ifnbeta As A Pharmacodynamic Marker In Vsv-Ifnbeta-Nis Oncolytic Therapy |
| HK40088918A | Detection Assays For Coronavirus Neutralizing Antibodies |
| MX2022013030A | Detection Assays For Coronavirus Neutralizing Antibodies |
| IN202117045835A | Ifnbeta As A Pharmacodynamic Marker In Vsv-Ifnbeta-Nis Oncolytic Therapy |
| MX2021011748A | Ifnbeta As A Pharmacodynamic Marker In Vsv-Ifnbeta-Nis Oncolytic Therapy. |
| ZA202107708A | Ifnbeta As A Pharmacodynamic Marker In Vsv-Ifnbeta-Nis Oncolytic Therapy |
| NZ793042A | Detection Assays For Coronavirus Neutralizing Antibodies |
| NZ780590A | Ifnbeta As A Pharmacodynamic Marker In Vsv-Ifnbeta-Nis Oncolytic Therapy |
| WO2021212096A1 | Detection Assays For Coronavirus Neutralizing Antibodies |
| WO2021212101A1 | Compositions For Treating And/Or Preventing Coronavirus Infections |
| WO2020198652A1 | Ifnbeta As A Pharmacodynamic Marker In Vsv-Ifnbeta-Nis Oncolytic Therapy |
What are Vyriad key innovation segments?
What Technologies are Covered by Vyriad?
The chart below distributes patents filed by Vyriad